Chronic foot ulceration is one of the major comorbid challenges associated with the manifestation of Type-2 Diabetic Mellitus and is responsible for high mortality rates, requiring the development of a localized drug delivery system (DDS) that can deliver the drug payload while also facilitating wound closure. Although nanofibers may be produced in many ways, electrospinning is one of the most versatile methods. Nanofiber-based DDSs show a substantial influence on targeted drug delivery, faster wound healing, and chronic wound closure. Electrospun nanofibers have evolved over time from simple nanofibers to new generations of nanofibers such as blend, composite, core-shell electrospun, and hybrid nanofibers, each with unique physicochemical and mechanochemical properties, giving distinct advantages to the respective nanofibers for better diabetic wound management. Optimizing the parameters involved in the preparation of nanofibers, which can be classified as static, processing and environmental parameters, is critical for process reproducibility, ensuring the desired properties of nanofibers, maintaining uniformity and maximizing the performance of electrospinning. Electrospun nanofibers are a suitable platform for treating chronic wounds such as diabetic foot ulcers. However, clinically using nanofiber-based DDSs as a localized wound therapy platform requires comprehensive physicochemical and mechanochemical characterization, as well as rigorous in-vitro and in-vivo drug release and wound healing efficacy testing

.